Skip to main content

Table 3 Changes in haemoglobin level, white blood cell and CD4 count during treatment among pulmonary tuberculosis patients with (n = 197) or without (n = 1008) diabetes

From: The role of diabetes co-morbidity for tuberculosis treatment outcomes: a prospective cohort study from Mwanza, Tanzania

  Patients without diabetes Patients with diabetes  
  (n = 2008) (n = 197)  
  Mean (95% CI) Mean (95% CI) P
Haemoglobin, g pr. dL    
 Baseline 10.8 (10.6; 10.9) 10.7 (10.4; 11.0)  
 2 months 12.3 (12.2; 12.5) 11.7 (11.4; 12.0)  
  Increase 1.6 (1.4; 1.7) 1.0 (0.7; 1.3)  
  Difference 0.6 (0.3; 0.9)   < 0.001
 5 months 13.0 (12.8; 13.1) 12.4 (12.1; 12.7)  
  Increase 2.2 (2.1; 2.3) 1.7 (1.4; 2.0)  
  Difference 0.5 (0.2; 0.9)   0.004
White blood cell count (total), 109 cells pr. L    
 Baseline 6.4 (6.3; 6.6) 6.8 (6.5; 7.1)  
 2 months 4.7 (4.6; 4.8) 5.0 (4.7; 5.3)  
  Increase −1.7 (−1.9; -1.6) −1.7 (−2.1; -1.4)  
  Difference 0.02 (−0.3; 0.4)   0.918
 5 months 4.3 (4.1; 4.4) 4.6 (4.3; 4.9)  
  Increase −2.2 (−2.3; -2.0) −2.2 (−2.5; -1.8)  
  Difference −0.03 (−0.4; 0.3)   0.889
Neutrophil granulocytes, 109 cells pr. L    
 Baseline 4.1 (4.0; 4.2) 4.6 (4.4; 4.8)  
 2 months 2.3 (2.2; 2.4) 2.6 (2.4; 2.8)  
  Increase −1.8 (−2.0; -1.7) −2.0 (−2.2; -1.7)  
  Difference 0.1 (−0.2; 0.4)   0.493
 5 months 1.8 (1.7; 2.0) 2.2 (2.0; 2.5)  
  Increase −2.3 (−2.4; -2.1) −2.3 (−2.6; -2.1)  
  Difference 0.1 (−0.2; 0.4)   0.658
CD4 count, cells pr. μL    
 Baseline 425.9 (408.9; 442.8) 409.2 (370.6; 447.8)  
 2 months 477.5 (459.9; 495.2) 435.1 (393.7; 476.5)  
  Increase 51.7 (29.7; 73.6) 25.9 (−25.0; 76.8)  
  Difference 25.7 (−29.7; 81.2)   0.362
 5 months 436.2 (417.7; 454.6) 396.6 (353.7; 439.6)  
  Increase 10.3 (−12.3; 32.9) −12.5 (−64.6; 39.6)  
  Difference 22.8 (−33.9; 79.6)   0.431
  1. Data are mean (95% confidence interval) based on a linear mixed-effects model, adjusted for age, sex, HIV status, alpha-1 glycoprotein, smoking habits, alcohol intake, and nutritional intervention.